Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents

Trial Profile

Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms MOCHA
  • Most Recent Events

    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top